relapsed non hodgkin lymphoma

Showing 1 - 20 of 20

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma Trial in Sacramento (biological, radiation, procedure, drug)

Active, not recruiting
  • Refractory Non Hodgkin Lymphoma
  • Relapsed Non Hodgkin Lymphoma
  • rituximab
  • +7 more
  • Sacramento, California
    University of California Davis
Nov 28, 2022

Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL Trial in Houston

Recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • +4 more
  • CD19.CAR-aNKT cells
  • +2 more
  • Houston, Texas
  • +1 more
Aug 19, 2022

Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,

Recruiting
  • Lymphoma, Non-Hodgkin
  • +6 more
  • CB-010
  • +2 more
  • Scottsdale, Arizona
  • +7 more
Aug 19, 2022

Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Poland, United

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +6 more
  • Cincinnati, Ohio
  • +4 more
Aug 3, 2022

Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial in Miami (Mosunetuzumab,

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +2 more
  • Miami, Florida
    University of Miami
Aug 3, 2022

Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +2 more
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
  • Calgary, Alberta, Canada
  • +5 more
Jul 18, 2022

Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Cleveland (Loncastuximab tesirine, Venetoclax)

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cance
May 20, 2022

Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma Trial in Boston (Anakinra, Axicabtagene

Recruiting
  • Non Hodgkin Lymphoma
  • +5 more
  • Boston, Massachusetts
  • +1 more
Oct 28, 2021

Relapsed Non Hodgkin Lymphoma Trial in Worldwide (Venetoclax)

Active, not recruiting
  • Relapsed Non Hodgkin Lymphoma
  • Aalborg, Denmark
  • +16 more
Oct 12, 2021

Polatuzumab Vedotin in Relapsed and Refractory Diffuse Large B

Completed
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Lymphoma
    • Taipei, Taiwan
      National Taiwan University Hospital
    Aug 8, 2021

    Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)

    Unknown status
    • Relapsed Non Hodgkin Lymphoma
    • Refractory Non-Hodgkin Lymphoma
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jul 30, 2021

    ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell

    Recruiting
    • Relapsed Non Hodgkin Lymphoma
    • Refractory Non-Hodgkin Lymphoma
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow University
      Jun 7, 2021

      Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Mexico City (Rituximab, Carboplatin, Cytarabine

      Completed
      • Relapsed Non Hodgkin Lymphoma
      • Refractory Non-Hodgkin Lymphoma
      • Mexico City, Azcapotzalco, Mexico
        Hospital Especialidades Centro Medico La Raza
      May 15, 2021

      Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Seoul (Rituximab, Fludarabine, Cyclophosphamide)

      Unknown status
      • Relapsed Non Hodgkin Lymphoma
      • Refractory Non-Hodgkin Lymphoma
      • Seoul, Korea, Republic of
      • +2 more
      Jul 26, 2020

      Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT

      Completed
      • Malignant Lymphoma
      • +3 more
        • (no location specified)
        Jul 8, 2020

        Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Maywood (Total body irradiation)

        Completed
        • Relapsed Non Hodgkin Lymphoma
        • Refractory Non-Hodgkin Lymphoma
        • Total body irradiation
        • Maywood, Illinois
          Patrick Stiff, MD
        Aug 19, 2019

        Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, CAR - T CD19/CD20/CD22/CD30 Trial in Suzhou (CAR-T)

        Unknown status
        • Relapsed Non Hodgkin Lymphoma
        • +2 more
        • CAR-T
        • Suzhou, Jiangsu, China
          the First Affiliated Hospital of Soochow University
        Apr 14, 2019

        Diffuse Large B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Seoul (azacitidine plus

        Not yet recruiting
        • Diffuse Large B Cell Lymphoma
        • +2 more
        • azacitidine plus R-GDP
        • Seoul, Korea, Republic of
          Seoul National University Hospital
        Oct 23, 2018

        Relapsed Non Hodgkin Lymphoma Trial in Zhengzhou (CAR19 T cells carrying cytoplasmic activated PD-1)

        Unknown status
        • Relapsed Non Hodgkin Lymphoma
        • CAR19 T cells carrying cytoplasmic activated PD-1
        • Zhengzhou, Henan, China
          Henan Cancer Hospital
        May 29, 2018

        Hematologic Cancer, Relapse Leukemia, Relapsed Adult ALL Trial in Montreal (GLIDE)

        Unknown status
        • Hematologic Cancer
        • +8 more
        • GLIDE
        • Montreal, Quebec, Canada
          CIUSSS d l'Est-de-l'Île-de-Montréal
        Dec 4, 2017